Skip to content

HOPE Trial hCG or Progesterone Effect on Recurrent Pregnancy Loss

hCG or Progesterone Effect on Unexplained Recurrent Pregnancy Loss

Status
Withdrawn
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05365464
Acronym
HOPE
Enrollment
0
Registered
2022-05-09
Start date
2022-05-31
Completion date
2025-12-31
Last updated
2022-05-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent Pregnancy Loss Without Current Pregnancy

Brief summary

Up to half of all cases of recurrent pregnancy loss are unexplained (uRPL). Evidence points towards endometriosis and progesterone resistance as an underlying cause of uRPL. Previous non-RCT studies have suggested the luteal hCG provides a useful treatment for uRPL. We propose performing a randomized controlled trial to compare mid-luteal hCG with oral progesterone to prevent early pregnancy losses. the endpoint will be ongoing pregnancy and live birth rates. Equal numbers of patients will be randomized to each group.

Detailed description

Fifty (50) patients with unexplained recurrent pregnancy loss, defined as 2 or more losses. Workup will exclude structural, genetic, hormonal, and anti-phospholipid syndrome-related causes of RPL. Women with unexplained RPL will be randomized to receive a mid-luteal injection of ovidril (250 ug) 1 week after ovulation vs prometrium (200 mg qhs) starting 4 days after ovulation. If pregnant, prometrium will be continued until 8 weeks of pregnancy. If pregnancy does not occur, subjects will be allowed to repeat this protocol for up to 3 cycles. Outcomes will be listed as not pregnant, biochemical pregnancy, miscarriage or ongoing pregnancy for each cycle. Endpoints of pregnant cycles will be compared for pregnancy rate, miscarriage rate, ongoing pregnancy rate and live birth rate.

Interventions

DRUGProgesterone Pill

Orally active progesterone

DRUGhCG

Given by subcutaneous injection

Sponsors

Wake Forest University Health Sciences
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

RCT

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 42 Years
Healthy volunteers
No

Inclusion criteria

* 2 first trimester losses * unexplained recurrent pregnancy loss

Exclusion criteria

* Antiphospholipid syndrome * uterine septum * Asherman's syndrome * Paternal or maternal genetic abnormalities (i.e. balanced translocation) * Endocrine causes of RPL (thyroid, diabetes, hyperprolactinemia)

Design outcomes

Primary

MeasureTime frameDescription
Miscarriage4 to 11 weeksLoss of pregnancy before 11 weeks of pregnancy
Ongoing pregnancy8 weeksSuccessgful pregnancy beyond 8 weeks of gestation with a heart beat

Secondary

MeasureTime frameDescription
Live birth rate40 weeksViable successful delivery of a life baby

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026